210 related articles for article (PubMed ID: 8112391)
1. Epibatidine is a nicotinic analgesic.
Qian C; Li T; Shen TY; Libertine-Garahan L; Eckman J; Biftu T; Ip S
Eur J Pharmacol; 1993 Dec; 250(3):R13-4. PubMed ID: 8112391
[TBL] [Abstract][Full Text] [Related]
2. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.
Sullivan JP; Decker MW; Brioni JD; Donnelly-Roberts D; Anderson DJ; Bannon AW; Kang CH; Adams P; Piattoni-Kaplan M; Buckley MJ
J Pharmacol Exp Ther; 1994 Nov; 271(2):624-31. PubMed ID: 7965777
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity.
Rupniak NM; Patel S; Marwood R; Webb J; Traynor JR; Elliott J; Freedman SB; Fletcher SR; Hill RG
Br J Pharmacol; 1994 Dec; 113(4):1487-93. PubMed ID: 7889306
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine.
Bonhaus DW; Bley KR; Broka CA; Fontana DJ; Leung E; Lewis R; Shieh A; Wong EH
J Pharmacol Exp Ther; 1995 Mar; 272(3):1199-203. PubMed ID: 7891333
[TBL] [Abstract][Full Text] [Related]
5. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
[TBL] [Abstract][Full Text] [Related]
6. Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography.
Sihver W; Gillberg PG; Nordberg A
Neuroscience; 1998 Aug; 85(4):1121-33. PubMed ID: 9681951
[TBL] [Abstract][Full Text] [Related]
7. Epibatidine, a potent analgetic and nicotinic agonist.
Badio B; Daly JW
Mol Pharmacol; 1994 Apr; 45(4):563-9. PubMed ID: 8183234
[TBL] [Abstract][Full Text] [Related]
8. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists.
Khan IM; Buerkle H; Taylor P; Yaksh TL
Neuropharmacology; 1998 Dec; 37(12):1515-25. PubMed ID: 9886674
[TBL] [Abstract][Full Text] [Related]
9. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.
Houghtling RA; Dávila-García MI; Kellar KJ
Mol Pharmacol; 1995 Aug; 48(2):280-7. PubMed ID: 7651361
[TBL] [Abstract][Full Text] [Related]
10. Genetic approaches identify differential roles for alpha4beta2* nicotinic receptors in acute models of antinociception in mice.
Damaj MI; Fonck C; Marks MJ; Deshpande P; Labarca C; Lester HA; Collins AC; Martin BR
J Pharmacol Exp Ther; 2007 Jun; 321(3):1161-9. PubMed ID: 17371806
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity data of some new epibatidine analogues.
Seerden JP; Tulp MT; Scheeren HW; Kruse CG
Bioorg Med Chem; 1998 Nov; 6(11):2103-10. PubMed ID: 9881100
[TBL] [Abstract][Full Text] [Related]
12. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
Alkondon M; Albuquerque EX
J Pharmacol Exp Ther; 1995 Aug; 274(2):771-82. PubMed ID: 7543571
[TBL] [Abstract][Full Text] [Related]
13. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
Parker MJ; Beck A; Luetje CW
Mol Pharmacol; 1998 Dec; 54(6):1132-9. PubMed ID: 9855644
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration.
Flores CM; Dávila-García MI; Ulrich YM; Kellar KJ
J Neurochem; 1997 Nov; 69(5):2216-9. PubMed ID: 9349569
[TBL] [Abstract][Full Text] [Related]
15. Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta.
Han ZY; Zoli M; Cardona A; Bourgeois JP; Changeux JP; Le Novère N
J Comp Neurol; 2003 Jun; 461(1):49-60. PubMed ID: 12722104
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.
Whiteaker P; Jimenez M; McIntosh JM; Collins AC; Marks MJ
Br J Pharmacol; 2000 Oct; 131(4):729-39. PubMed ID: 11030722
[TBL] [Abstract][Full Text] [Related]
17. High affinity binding of epibatidine to serotonin type 3 receptors.
Drisdel RC; Sharp D; Henderson T; Hales TG; Green WN
J Biol Chem; 2008 Apr; 283(15):9659-65. PubMed ID: 17702741
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex.
Zhang X; Gong ZH; Fasth KJ; Långström B; Nordberg A
Neurochem Int; 1998; 32(5-6):435-41. PubMed ID: 9676742
[TBL] [Abstract][Full Text] [Related]
19. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
Warpman U; Nordberg A
Neuroreport; 1995 Nov; 6(17):2419-23. PubMed ID: 8747166
[TBL] [Abstract][Full Text] [Related]
20. Mecamylamine prevents tolerance but enhances whole brain [3H]epibatidine binding in response to repeated nicotine administration in rats.
McCallum SE; Caggiula AR; Booth S; Breese CR; Lee MJ; Donny EC; Leonard S; Sved AF
Psychopharmacology (Berl); 2000 May; 150(1):1-8. PubMed ID: 10867970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
